Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

ABS-201

Monoclonal antibody · Antagonist of prolactin receptor (PRLR) · developed by Absci Pty

Phase 1/2 Most advanced trial

ABSI Developer

1 Registered trials

What is ABS-201?

ABS-201 is an IgG1 monoclonal antibody that targets the prolactin receptor (PRLR). It is being studied for androgenetic alopecia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Monoclonal antibody
Targets: prolactin receptor (PRLR)
Mechanism: Antagonist of prolactin receptor (PRLR)
Therapy area: Dermatology
Developer: Absci Pty Ltd. (ABSI)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07317544	Phase 1/2	Androgenetic Alopecia (AGA)	Recruiting	ABSI

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Androgenetic Alopecia (AGA)Healthy Volunteers - Male and Female

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ABSI page.

Follow ABSI, the company behind ABS-201

See ABSI's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABSI catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z